SAMIRA is NeoCare’s development-stage platform concept for painless, rapid and non-invasive neonatal assessment. The platform direction focuses on three important newborn-care workflows: anemia, jaundice and oxygen saturation.
Anemia, jaundice and hypoxia-related oxygen-saturation issues remain important newborn-health concerns. Conventional testing often depends on blood sampling, laboratory infrastructure and waiting time before reports are available.
Blood-based testing may create emotional stress for newborns and parents, especially when repeated samples are required.
Laboratory testing can introduce waiting time, which may slow decisions and increase anxiety during newborn care.
Conventional workflows can require laboratory infrastructure, trained personnel and maintenance-heavy systems.
The technology direction combines optical/sensing-system thinking with parameter-estimation workflows. The website language remains validation-aware and avoids overclaiming current clinical readiness.
Hemoglobin-related assessment is part of the SAMIRA platform direction for neonatal anemia workflows.
Bilirubin-related assessment is part of the SAMIRA platform direction for neonatal jaundice monitoring workflows.
Oxygen-saturation workflow support is included in the platform direction for hypoxia-related newborn assessment.
The SAMIRA concept uses a non-invasive optical measurement approach that combines a light source, fiber/probe, spectrometer and user-interface workflow for estimating newborn-health parameters.
A simplified website-ready figure showing the SAMIRA optical assessment workflow.
Current newborn-assessment workflows are often fragmented across separate parameters and separate care steps. NeoCare is developing SAMIRA as a non-invasive, multi-parameter direction that aims to reduce friction while remaining validation-aware.
In many clinical pathways, hemoglobin, bilirubin and oxygen-related assessment are handled through separate devices, tests or decision steps rather than one integrated workflow.
SAMIRA is being developed to bring optical acquisition, signal processing and multi-parameter interpretation into a unified platform direction for newborn-care support.
NeoCare presents SAMIRA as a development-stage technology direction intended to support clinical workflows, with future claims guided by formal validation, clinical studies and regulatory pathways.
A staged roadmap from the SAMIRA benchtop platform to ASAMIR handheld deployment and connected reporting.
The development roadmap moves from prototype validation toward a more compact, trial-oriented device and mobile-style reporting. On the website, this is framed as a roadmap rather than a current commercial claim.
The potential market for newborn testing and related assessment workflows is substantial. The figures below are directional market indicators for website communication.
Earlier validation activity indicates promising alignment with conventional testing. For public website use, this should be framed carefully: formal revalidation remains necessary for regulatory and market-specific purposes.
SAMIRA should be positioned as a technology direction intended to support clinical workflows, not replace standard-of-care testing or clinician judgement. Future indications, claims and use environments must be defined through validation and regulatory pathways.
NeoCare is also exploring a future product-roadmap direction for urinary bladder cancer detection from unprocessed urine samples. This is included as a pipeline item, separate from the current neonatal SAMIRA positioning.
Positioned as a future roadmap item within the broader NeoCare pipeline.
For MedTech partnerships, neonatal assessment discussions, validation planning or collaboration opportunities, contact Dr. Singh directly.